CClinicalTrials.gg
Sign In
Not yet recruitingNCT06286241Step down wardUpdated Mar 15, 2024

Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room

An observational study in Multiple Myeloma, sponsored by Siriraj Hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Siriraj Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 3 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
344
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this observational study is to comparison of the complications in multiple myeloma patients who received autologous stem cell transplantation between in HEPA-filtered room and non-HEPA-filtered room. The main questions it aims to answer are:

  • The incidence of febrile neutropenia, infection, and duration of hospital stay
  • 2-year progression free survival Participants will be collected the data of baseline diagnosis, treatment, treatment results and complications during admission and follow-up visits from hospital medical record.
02

Conditions studied

  • Multiple Myeloma

Keywords

  • multiple myeloma
  • autologous stem cell transplantation
  • HEPA-filtered room
  • non-HEPA-filtered room
03

In context

Multiple Myeloma

3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.

This study's planned enrollment of 344 is above the median of 140 across 468 observational studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Siriraj Hospital is the lead sponsor of 95 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

multiple myeloma patients who received autologous stem cell transplantation

Inclusion criteria

  • aged 18 - 65 years old
  • Patients with multiple myeloma undergoing treatment with autologous stem cell transplantation and having a Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score less than or equal to 2
  • Patients must provide signed consent to participate in the research if they undergo ASCT after the study has been approved.
  • If patients undergo ASCT before the study approval, retrospective data will be collected.

Exclusion criteria

Exclusion Criteria:

  • Patients with concomitant other types of cancer
  • Patients who refuse to participate in the study.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
344 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • HEPA-filtered room

    multiple myeloma patients who received autologous stem cell transplantation were admitted in HEPA-filtered room

  • non-HEPA-filtered room

    multiple myeloma patients who received autologous stem cell transplantation were admitted in non-HEPA-filtered room

06

What researchers measure

Primary outcomes

  1. febrile neutropenia

    incidence of febrile neutropenia

    Time frame: during admission

  2. Infection

    incidence of Infection

    Time frame: during admission

  3. duration of admission

    duration of admission

    Time frame: during admission

  4. progression free survival

    duration of survival

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Need a consensus from colleagues

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06286241
Lead sponsor
Siriraj Hospital
Responsible party
Chutima Kunacheewa (lecturer, Siriraj Hospital) — Principal investigator
First posted
Feb 29, 2024
Start date
Mar 25, 2024 (estimated)
Primary completion
Jun 30, 2024 (estimated)
Completion
Jul 30, 2024 (estimated)
Last update
Mar 15, 2024

Study contacts

Chutima Kunacheewa, MD
Contact
chutima.kua@mahidol.ac.th
+66896790959
Weerapat Owattanapanich, MD
Contact
weerapat.owa@mahidol.ac.th
+66891081983

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Myeloma→

Other studies from this sponsor

Siriraj Hospital

Start the discussion